Goodwill is tested annually for impairment at the reporting unit level during the fourth quarter or earlier upon the occurrence of certain events or substantive changes in circumstances. There were no indicators of impairment in the three months ended March 31, 2023. The balance of the Company's goodwill was $39.6 million as of March 31, 2023 and $37.5 million as of December 31, 2022.

The following table presents details of the Company’s intangible assets as of March 31, 2023 ($ in thousands):


	March 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation		Net Carrying Amount		Weighted Average Remaining Useful Life (In Years)
Intangible assets with finite lives:
Acquired and developed technology	$	36,517	$	(15,931)	$	(2,336)	$	18,250	7.5
Customer relationships	24,908		(7,852)		(2,067)		14,989		9.5
Commercialization rights	11,579		(3,549)		—		8,030		6.3
Trademarks and tradenames	4,860		(1,434)		(308)		3,118		9.2

Total intangible assets with finite lives	77,864		(28,766)		(4,711)		44,387
Acquired in-process technology	1,250		—		—		1,250
Total intangible assets	$	79,114	$	(28,766)	$	(4,711)	$	45,637

The following table presents details of the Company’s intangible assets as of December 31, 2022 ($ in thousands):


	December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation		Net Carrying Amount		Weighted Average Remaining Useful Life (In Years)
Intangible assets with finite lives:
Acquired and developed technology	$	35,747	$	(15,138)	$	(2,369)	$	18,240	7.5
Customer relationships	21,898		(7,459)		(2,104)		12,335		9.0
Commercialization rights	11,579		(3,233)		—		8,346		6.6
Trademarks and tradenames	4,540		(1,345)		(315)		2,880		8.5

Total intangible assets with finite lives	73,764		(27,175)		(4,788)		41,801
Acquired in-process technology	1,250		—		—		1,250
Total intangible assets	$	75,014	$	(27,175)	$	(4,788)	$	43,051

In June 2021, the Company acquired commercialization rights in an exclusive partnership for comprehensive data analytics in relation to NGS-based metagenomics testing for infectious diseases. In 2022, the Company incurred additional costs related to this partnership of $1.0 million. These are included within commercialization rights as of March 31, 2023.

In June 2021, the Company acquired the Transplant Hero patient application. The patient application is included in Acquired and developed technology as of March 31, 2023.

In the fourth quarter of 2021, acquisition of intangible assets increased $13.4 million primarily from business combinations. These acquisitions included $4.7 million of Acquired and developed technology, $2.5 million of Commercialization rights, $3.7 million of Customer relationships, $2.2 million of Trademarks and tradenames and $0.3 million of Other intangible assets.

Intangible assets are carried at cost less accumulated amortization. Amortization expenses are recorded to cost of testing services, cost of product, cost of patient and digital solutions, and sales and marketing expenses in the condensed consolidated statements of operations.


	Three Months Ended March 31,
	2023		2022
Cost of testing services	$	329	$	329
Cost of product	418		453
Cost of patient and digital solutions	248		236
Sales & marketing	595		605
Total	$	1,590	$	1,623

The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of March 31, 2023 (in thousands):


Years Ending December 31,	Cost of Testing Services		Cost of Product		Cost of Patient and Digital Solutions		Sales and Marketing		Total
Remainder of 2023	$	987	$	1,263	$	761	$	1,850	$	4,861
2024	1,316		1,684		779		2,467		6,246
2025	1,316		1,684		610		2,467		6,077
2026	1,316		745		610		2,465		5,136
2027	1,316		745		610		2,451		5,122
Thereafter	2,825		3,299		1,605		9,216		16,945
Total future amortization expense	$	9,076	$	9,420	$	4,975	$	20,916	$	44,387